Lunai Bioworks Inc.

Snapshot

Lunai is a pre-clinical, pre-revenue AI biotech that just told the SEC it has substantial doubt about continuing as a going concern.

What's Happening Right Now

• Tue 13th Oct '26 · Going concern: Lunai's fiscal 2026 10-K disclosed substantial doubt about its ability to continue as a going concern, with less than one month of available cash as of October 13, 2026, a $514 million accumulated deficit, and only $51,992 of revenue from a single customer; the company remains pre-clinical with no approved products.
• Fri 9th Oct '26 · Trading halt request: On October 9, 2026, Lunai formally asked Nasdaq to suspend trading in its stock, citing court-discovered evidence of short-selling, locate deficiencies, and failures to deliver from its litigation against Seven Points Capital; no Nasdaq decision had been made as of the filing.
• Tue 22nd Sep '26 · Partnership: On September 22, 2026, Lunai signed an exclusive worldwide license agreement with Tanaist adding human cellular phenotyping to its AI-driven Parkinson's disease discovery platform, with no financial terms disclosed.
• Tue 4th Aug '26 · Short-selling suit: Lunai amended its Delaware lawsuit to name 10 defendants, including three broker-dealers, alleging a naked short-selling scheme with 29.6 million failed-to-deliver shares and a single session with volume 15.3 times its issued shares; it is seeking treble damages under RICO.
• Tue 4th Aug '26 · Collaboration: On August 4, 2026, Lunai signed a definitive Master Collaboration Agreement with BrainStorm Therapeutics combining AI patient stratification with brain organoid models for Parkinson's disease, targeting an initial data readout in the first half of 2027.